The mitotic serine/threonine kinase Aurora2/AIK is regulated by phosphorylation and degradation von WALTER, Annette O, SEGHEZZI, Wolfgang, KORVER, Wouter, SHEUNG, Julie, LEES, Emma

Volltext

Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC von Walter, Annette O, Sjin, Robert Tjin Tham, Haringsma, Henry J, Ohashi, Kadoaki, Sun, Jing, Lee, Kwangho, Dubrovskiy, Aleksandr, Labenski, Matthew, Zhu, Zhendong, Wang, Zhigang, Sheets, Michael, St Martin, Thia, Karp, Russell, van Kalken, Dan, Chaturvedi, Prasoon, Niu, Deqiang, Nacht, Mariana, Petter, Russell C, Westlin, William, Lin, Kevin, Jaw-Tsai, Sarah, Raponi, Mitch, Van Dyke, Terry, Etter, Jeff, Weaver, Zoe, Pao, William, Singh, Juswinder, Simmons, Andrew D, Harding, Thomas C, Allen, Andrew

Volltext

Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling von Graham, Keith, Lienau, Philip, Bader, Benjamin, Prechtl, Stefan, Naujoks, Jan, Lesche, Ralf, Weiske, Joerg, Kuehnlenz, Julia, Brzezinka, Krzysztof, Potze, Lisette, Zanconato, Francesca, Nicke, Barbara, Montebaur, Anna, Bone, Wilhelm, Golfier, Sven, Kaulfuss, Stefan, Kopitz, Charlotte, Pilari, Sabine, Steuber, Holger, Hayat, Sikander, Kamburov, Atanas, Steffen, Andreas, Schlicker, Andreas, Buchgraber, Philipp, Braeuer, Nico, Font, Nuria Aiguabella, Heinrich, Tobias, Kuhnke, Lara, Nowak-Reppel, Katrin, Stresemann, Carlo, Steigemann, Patrick, Walter, Annette O., Blotta, Simona, Ocker, Matthias, Lakner, Ashley, von Nussbaum, Franz, Mumberg, Dominik, Eis, Knut, Piccolo, Stefano, Lange, Martin

Volltext

Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies von Bahleda, Rastislav, Grilley-Olson, Juneko E, Govindan, Ramaswamy, Barlesi, Fabrice, Greillier, Laurent, Perol, Maurice, Ray-Coquard, Isabelle, Strumberg, Dirk, Schultheis, Beate, Dy, Grace K, Zalcman, Gérard, Weiss, Glen J, Walter, Annette O, Kornacker, Martin, Rajagopalan, Prabhu, Henderson, David, Nogai, Hendrik, Ocker, Matthias, Soria, Jean-Charles

Volltext

The discovery of tetrahydro-β-carbolines as inhibitors of the kinesin Eg5 von Barsanti, Paul A., Wang, Weibo, Ni, Zhi-Jie, Duhl, David, Brammeier, Nathan, Martin, Eric, Bussiere, Dirksen, Walter, Annette O.

Volltext

The Shp-2 tyrosine phosphatase activates the Src tyrosine kinase by a non-enzymatic mechanism von WALTER, A. O, PENG, Z.-Y, CARTWRIGHT, C. A

Volltext

Abstract 3022: BAY 1143572, a first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in Phase I, shows convincing anti-tumor activity in pr... von Scholz, Arne, Oellerich, Thomas, Hussain, Akhtar, Lindner, Sarah, Luecking, Ulrich, Walter, Annette O., Ellinghaus, Peter, Valencia, Ray, von Nussbaum, Franz, Mumberg, Dominik, Brands, Michael, Ince, Stuart, Serve, Hubert, Ziegelbauer, Karl

Volltext

Inhibition of Cdc7/Dbf4 kinase activity affects specific phosphorylation sites on MCM2 in cancer cells von Charych, Deborah H., Coyne, Mazie, Yabannavar, Asha, Narberes, Jamie, Chow, Sylvia, Wallroth, Marco, Shafer, Cynthia, Walter, Annette O.

Volltext

Abstract 4816: Anetumab ravtansine has monotherapy efficacy in mesothelin positive patient-derived NSCLC tumor models and in a syngeneic tumor model in immunocompetent mice von Sommer, Anette, Lejeune, Pascale, Hoff, Sabine, Walter, Annette O., Berndt, Sandra, Roese, Lars, Schlicker, Andreas, Wick, Michael J., Elbi, Cem, Mumberg, Dominik, Schatz, Christoph

Volltext

Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multice... von Santin, Alessandro D, Vergote, Ignace, Gonzalez-Martin, Antonio, Moore, Kathleen, Oaknin, Ana, Romero, Ignacio, Diab, Sami, Copeland, Larry J, Monk, Bradley J, Coleman, Robert L, Herzog, Thomas J, Siegel, Jonathan, Kasten, Linda, Schlicker, Andreas, Schulz, Anke, Kochert, Karl, Walter, Annette O, Childs, Barrett H, Elbi, Cem, Bulat, Iurie

Volltext

Abstract 3349: Preclinical efficacyof the PARP inhibitor rucaparib (AG014699/PF-01367338) as a monotherapy and incombination with PI3K inhibition von Robillard, Liliane, Harding, Thomas C., Walter, Annette O.

Volltext

Abstract DDT02-02: BAY 1143572: A first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in Phase I, inhibits MYC and shows convincing anti... von Scholz, Arne, Luecking, Ulrich, Siemeister, Gerhard, Lienau, Philip, Boemer, Ulf, Ellinghaus, Peter, Walter, Annette O., Valencia, Ray, Ince, Stuart, von Nussbaum, Franz, Mumberg, Dominik, Brands, Michael, Ziegelbauer, Karl

Volltext

Abstract 3022: BAY 1143572, a first-in-class, highly selective, potent and orally available inhibitor of PTEFbCDK9 currently in Phase I, shows convincing anti-tumor activity in pre... von Scholz, Arne, Oellerich, Thomas, Hussain, Akhtar, Lindner, Sarah, Luecking, Ulrich, Walter, Annette O, Ellinghaus, Peter, Valencia, Ray, von Nussbaum, Franz, Mumberg, Dominik, Brands, Michael, Ince, Stuart, Serve, Hubert, Ziegelbauer, Karl

Volltext

Abstract A114: In vitro acquired resistance to the mutant selective EGFR inhibitor CO-1686 is associated with epithelial-mesenchymal transition (EMT) von Haringsma, Henry, Walter, Annette O., Tjin Tham Sjin, Robert, Allen, Andrew, Harding, Thomas C., Simmons, Andrew D.

Volltext

Abstract B120: Preclinical assessment of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC von Simmons, Andrew D., Haringsma, Henry J., Walter, Annette O., Tjin Tham Sjin, Robert, Weaver, Zoe, Allen, Andrew, Harding, Thomas C.

Volltext

Abstract 3244: Role of epithelial-mesenchymal transition (EMT) in sensitivity to CNX-2006, a novel mutant-selective EGFR inhibitor which overcomes in vitro T790M-mediated resistanc... von Galvani, Elena, Giovannetti, Elisa, Walter, Annette O., Tjin, Robert, Dekker, Henk, Petronini, Pier Giorgio, Smit, Egbert F., Peters, Godefridus J.

Volltext

Abstract 1791: CO-1686, a novel mutant-selective EGFR inhibitor, overcomes T790M mediated resistance in Non-Small Cell Lung Cancer (NSCLC) von Walter, Annette O., Tjin, Robert, Haringsma, Henry, Lin, Kevin, Dubrovskiy, Alex, Lee, Kwangho, Martin, Thia St, Karp, Russell, Zhu, Zhendong, Nu, Deqiang, Nacht, Mariana, Suda, Kenichi, Mitsudomi, Tetsuya, Petter, Russell C., Westlin, William F., Singh, Juswinder, Raponi, Mitch, Allen, Andrew

Volltext

Compuestos de pirazol y triazol como inhibidores de KSP von XIA, Yi, MENDENHALL, Kris G, RENHOWE, Paul A, WALTER, Annette O, DUHL, David, BARSANTI, Paul A

Volltext bestellen

INHIBIDORES DE CINESINA COMO PRODUCTOS TERAPÉUTICOS PARA EL CÁNCER von WALTER ANNETTE O, RENHOWE PAUL, FAURE MICHEL, ABRAMS TINYA, BARSANTI PAUL, DUHL DAVID

Volltext bestellen

COMPUESTOS DE PIRAZOL Y TRIAZOL SUSTITUÍDOS COMO INHIBIDORES DE KSP von PAUL A. RENHOWE, DAVID DUHL, YI XIA, ANNETTE O. WALTER, PAUL A. BARSANTI, KRIS G. MENDENHALL

Volltext bestellen